PURE — Pure Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00- $7.30m
- $11.07m
- $1.96m
- 32
- 18
- 28
- 14
Annual cashflow statement for Pure Biosciences, fiscal year end - July 31st, USD millions except per share, conversion factor applied.
2020 July 31st | 2021 July 31st | 2022 July 31st | 2023 July 31st | 2024 July 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 0.004 | -2.32 | -3.49 | -3.96 | -3.35 |
| Depreciation | |||||
| Non-Cash Items | 0.791 | 0.991 | 0.757 | 0.673 | 0.274 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.318 | -0.011 | 0.103 | -0.107 | 0.397 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 0.669 | -1.17 | -2.42 | -3.28 | -2.53 |
| Capital Expenditures | -0.058 | -0.521 | -0.081 | -0.033 | 0 |
| Purchase of Fixed Assets | |||||
| Cash from Investing Activities | -0.058 | -0.521 | -0.081 | -0.033 | 0 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 2.83 | 0.239 | 3.5 | 1.01 | 1.78 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 3.44 | -1.45 | 1 | -2.3 | -0.746 |